vs
EXACT SCIENCES CORP（EXAS）与罗技（LOGI）财务数据对比。点击上方公司名可切换其他公司
罗技的季度营收约是EXACT SCIENCES CORP的1.6倍（$1.4B vs $878.4M），罗技净利率更高（17.7% vs -9.8%，领先27.4%），EXACT SCIENCES CORP同比增速更快（23.1% vs 6.1%），罗技自由现金流更多（$465.6M vs $120.4M），过去两年罗技的营收复合增速更高（18.5% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
罗技国际是总部位于瑞士洛桑的跨国企业，专注于计算机外设及相关软件的研发与生产，在欧洲、亚洲、大洋洲、美洲均设有分支机构，为瑞士市场指数成分股，同时在纳斯达克交易所挂牌上市。
EXAS vs LOGI — 直观对比
营收规模更大
LOGI
是对方的1.6倍
$878.4M
营收增速更快
EXAS
高出17.1%
6.1%
净利率更高
LOGI
高出27.4%
-9.8%
自由现金流更多
LOGI
多$345.2M
$120.4M
两年增速更快
LOGI
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.4B |
| 净利润 | $-86.0M | $251.0M |
| 毛利率 | 70.1% | 43.2% |
| 营业利润率 | -9.4% | 20.1% |
| 净利率 | -9.8% | 17.7% |
| 营收同比 | 23.1% | 6.1% |
| 净利润同比 | 90.1% | 25.4% |
| 每股收益（稀释后） | $-0.45 | $1.69 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASLOGI
| Q4 25 | $878.4M | $1.4B | ||
| Q3 25 | $850.7M | $1.2B | ||
| Q2 25 | $811.1M | $1.1B | ||
| Q1 25 | $706.8M | $1.0B | ||
| Q4 24 | $713.4M | $1.3B | ||
| Q3 24 | $708.7M | $1.1B | ||
| Q2 24 | $699.3M | $1.1B | ||
| Q1 24 | $637.5M | $1.0B |
净利润EXASLOGI
| Q4 25 | $-86.0M | $251.0M | ||
| Q3 25 | $-19.6M | $170.7M | ||
| Q2 25 | $-1.2M | $146.0M | ||
| Q1 25 | $-101.2M | $144.1M | ||
| Q4 24 | $-864.6M | $200.1M | ||
| Q3 24 | $-38.2M | $145.5M | ||
| Q2 24 | $-15.8M | $141.8M | ||
| Q1 24 | $-110.2M | $167.6M |
毛利率EXASLOGI
| Q4 25 | 70.1% | 43.2% | ||
| Q3 25 | 68.6% | 43.4% | ||
| Q2 25 | 69.3% | 41.7% | ||
| Q1 25 | 70.8% | 43.1% | ||
| Q4 24 | 69.0% | 42.9% | ||
| Q3 24 | 69.4% | 43.6% | ||
| Q2 24 | 69.8% | 42.8% | ||
| Q1 24 | 70.0% | 43.2% |
营业利润率EXASLOGI
| Q4 25 | -9.4% | 20.1% | ||
| Q3 25 | -3.0% | 16.1% | ||
| Q2 25 | -0.3% | 14.1% | ||
| Q1 25 | -13.6% | 10.5% | ||
| Q4 24 | -122.8% | 17.5% | ||
| Q3 24 | -5.6% | 14.4% | ||
| Q2 24 | -3.8% | 14.1% | ||
| Q1 24 | -16.7% | 12.9% |
净利率EXASLOGI
| Q4 25 | -9.8% | 17.7% | ||
| Q3 25 | -2.3% | 14.4% | ||
| Q2 25 | -0.1% | 12.7% | ||
| Q1 25 | -14.3% | 14.3% | ||
| Q4 24 | -121.2% | 14.9% | ||
| Q3 24 | -5.4% | 13.0% | ||
| Q2 24 | -2.3% | 13.0% | ||
| Q1 24 | -17.3% | 16.6% |
每股收益（稀释后）EXASLOGI
| Q4 25 | $-0.45 | $1.69 | ||
| Q3 25 | $-0.10 | $1.15 | ||
| Q2 25 | $-0.01 | $0.98 | ||
| Q1 25 | $-0.54 | $0.94 | ||
| Q4 24 | $-4.69 | $1.32 | ||
| Q3 24 | $-0.21 | $0.95 | ||
| Q2 24 | $-0.09 | $0.92 | ||
| Q1 24 | $-0.60 | $1.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $1.8B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $2.3B |
| 总资产 | $5.9B | $4.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASLOGI
| Q4 25 | $964.7M | $1.8B | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | $858.4M | $1.5B | ||
| Q1 25 | $786.2M | $1.5B | ||
| Q4 24 | $1.0B | $1.5B | ||
| Q3 24 | $1.0B | $1.4B | ||
| Q2 24 | $946.8M | $1.5B | ||
| Q1 24 | $652.1M | $1.5B |
股东权益EXASLOGI
| Q4 25 | $2.4B | $2.3B | ||
| Q3 25 | $2.5B | $2.1B | ||
| Q2 25 | $2.5B | $2.2B | ||
| Q1 25 | $2.4B | $2.1B | ||
| Q4 24 | $2.4B | $2.1B | ||
| Q3 24 | $3.2B | $2.1B | ||
| Q2 24 | $3.2B | $2.2B | ||
| Q1 24 | $3.1B | $2.2B |
总资产EXASLOGI
| Q4 25 | $5.9B | $4.1B | ||
| Q3 25 | $5.9B | $3.7B | ||
| Q2 25 | $5.8B | $3.7B | ||
| Q1 25 | $5.7B | $3.5B | ||
| Q4 24 | $5.9B | $3.7B | ||
| Q3 24 | $6.7B | $3.6B | ||
| Q2 24 | $6.7B | $3.7B | ||
| Q1 24 | $6.4B | $3.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $480.5M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $465.6M |
| 自由现金流率自由现金流/营收 | 13.7% | 32.8% |
| 资本支出强度资本支出/营收 | 3.6% | 1.0% |
| 现金转化率经营现金流/净利润 | — | 1.91× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $903.6M |
8季度趋势，按日历期对齐
经营现金流EXASLOGI
| Q4 25 | $151.7M | $480.5M | ||
| Q3 25 | $219.9M | $228.8M | ||
| Q2 25 | $89.0M | $125.0M | ||
| Q1 25 | $30.8M | $129.7M | ||
| Q4 24 | $47.1M | $370.9M | ||
| Q3 24 | $138.7M | $166.0M | ||
| Q2 24 | $107.1M | $176.0M | ||
| Q1 24 | $-82.3M | $239.1M |
自由现金流EXASLOGI
| Q4 25 | $120.4M | $465.6M | ||
| Q3 25 | $190.0M | $212.3M | ||
| Q2 25 | $46.7M | $108.8M | ||
| Q1 25 | $-365.0K | $116.9M | ||
| Q4 24 | $10.7M | $356.6M | ||
| Q3 24 | $112.6M | $151.5M | ||
| Q2 24 | $71.2M | $161.4M | ||
| Q1 24 | $-120.0M | $228.8M |
自由现金流率EXASLOGI
| Q4 25 | 13.7% | 32.8% | ||
| Q3 25 | 22.3% | 17.9% | ||
| Q2 25 | 5.8% | 9.5% | ||
| Q1 25 | -0.1% | 11.6% | ||
| Q4 24 | 1.5% | 26.6% | ||
| Q3 24 | 15.9% | 13.6% | ||
| Q2 24 | 10.2% | 14.8% | ||
| Q1 24 | -18.8% | 22.6% |
资本支出强度EXASLOGI
| Q4 25 | 3.6% | 1.0% | ||
| Q3 25 | 3.5% | 1.4% | ||
| Q2 25 | 5.2% | 1.4% | ||
| Q1 25 | 4.4% | 1.3% | ||
| Q4 24 | 5.1% | 1.1% | ||
| Q3 24 | 3.7% | 1.3% | ||
| Q2 24 | 5.1% | 1.3% | ||
| Q1 24 | 5.9% | 1.0% |
现金转化率EXASLOGI
| Q4 25 | — | 1.91× | ||
| Q3 25 | — | 1.34× | ||
| Q2 25 | — | 0.86× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | — | 1.85× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.24× | ||
| Q1 24 | — | 1.43× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
LOGI
| Retail Gaming | $482.7M | 34% |
| Retail Keyboards Desktops | $254.6M | 18% |
| Retail Pointing Devices | $241.2M | 17% |
| Retail Video Collaboration | $193.3M | 14% |
| Retail Tablet And Other Accessories | $93.6M | 7% |
| Retail Webcams | $82.3M | 6% |
| Retail Headsets | $45.9M | 3% |
| Other Retail Products | $28.0M | 2% |
